



## **Geron to Present at the Stifel 2021 Virtual Healthcare Conference**

11/12/2021

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced that John A. Scarlett, M.D., Geron's Chairman and Chief Executive Officer, will present a company overview at the Stifel 2021 Virtual Healthcare Conference on Tuesday, November 16, 2021 at 2:40 p.m. ET.

A live webcast of the presentation will be available through the Investor Relations section of Geron's website under Events. Following the presentation, the webcast will be archived and available for replay for a period of 30 days.

### **About Geron**

Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMPactMF in refractory myelofibrosis. For more information about Geron, visit [www.geron.com](http://www.geron.com).

View source version on **businesswire.com**: <https://www.businesswire.com/news/home/20211112005451/en/>

Olivia Bloom  
Chief Financial Officer  
[investor@geron.com](mailto:investor@geron.com)  
[media@geron.com](mailto:media@geron.com)

Source: Geron Corporation